Cargando…

Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies

SIMPLE SUMMARY: Colorectal cancer (CRC) is the third most commonly diagnosed malignancy and the second most common cause of cancer-related mortality worldwide. Currently available targeted therapies for metastatic CRC mainly target vascular endothelial growth factor and epidermal growth factor recep...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Nannan, Cao, Yuepeng, Si, Chengshuai, Shao, Peng, Su, Guoqing, Wang, Ke, Bao, Jun, Yang, Liu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9600272/ https://www.ncbi.nlm.nih.gov/pubmed/36291943 http://dx.doi.org/10.3390/cancers14205160

Ejemplares similares

Immune checkpoint blockade therapy for BRAF mutant metastatic colorectal cancer: the efficacy, new strategies, and potential biomarkers
por: Zhong, Jie, et al.
Publicado: (2023)

CARF, As An Oncogene, Promotes Colorectal Cancer Stemness By Activating ERBB Signaling Pathway
por: Dong, Weiyi, et al.
Publicado: (2019)

Therapeutic Effect of Berberine on Insomnia Rats by ErbB Signaling Pathway
por: Wang, Qingquan, et al.
Publicado: (2020)

Aberrant methylation of ERBB pathway genes in sporadic colorectal cancer
por: Szmida, Elzbieta, et al.
Publicado: (2014)

Proliferation of Colorectal Cancer Is Promoted by Two Signaling Transduction Expression Patterns: ErbB2/ErbB3/AKT and MET/ErbB3/MAPK
por: Yao, Yong-Liang, et al.
Publicado: (2013)

Precision Medicine in Metastatic Colorectal Cancer: Targeting ERBB2 (HER-2) Oncogene
por: Torres-Jiménez, Javier, et al.
Publicado: (2022)

Development of a personalized therapeutic strategy for ERBB-gene-mutated cancers
por: Milewska, Malgorzata, et al.
Publicado: (2018)

Current Therapeutic Strategies in BRAF-Mutant Metastatic Colorectal Cancer
por: Grassi, Elisa, et al.
Publicado: (2021)

HER3- A key survival pathway and an emerging therapeutic target in metastatic colorectal cancer and pancreatic ductal adenocarcinoma
por: Desai, Omkar, et al.
Publicado: (2023)

Current material engineering strategies to prevent catheter encrustation in urinary tracts
por: Yao, Qin, et al.
Publicado: (2022)

ERBB4 confers metastatic capacity in Ewing sarcoma
por: Mendoza-Naranjo, Ariadna, et al.
Publicado: (2013)

FBXW7 and Its Downstream NOTCH Pathway Could be Potential Indicators of Organ-Free Metastasis in Colorectal Cancer
por: Li, Dongzheng, et al.
Publicado: (2022)

Targeting KRAS in metastatic colorectal cancer: current strategies and emerging opportunities
por: Porru, Manuela, et al.
Publicado: (2018)

Comparison of Management and Outcomes in ERBB2-Low vs ERBB2-Zero Metastatic Breast Cancer in France
por: de Calbiac, Ombline, et al.
Publicado: (2022)

The Association of ERBB2-Low Expression With the Efficacy of Cyclin-Dependent Kinase 4/6 Inhibitor in Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast Cancer
por: Bao, Kelvin K. H., et al.
Publicado: (2021)

Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3
por: Ross, Jeffrey S., et al.
Publicado: (2018)

Prognostic role of ERBB2, MET and VEGFA expression in metastatic colorectal cancer patients treated with anti-EGFR antibodies
por: Takahashi, Naoki, et al.
Publicado: (2016)

Refractory microsatellite stable metastatic colorectal cancer with ERBB2/ERBB3 mutation may be preferred population for regorafenib plus PD-1 inhibitor therapy: a real-world study
por: Dai, Xuan, et al.
Publicado: (2023)

Heterogeneous amplification of ERBB2 in primary lesions is responsible for the discordant ERBB2 status of primary and metastatic lesions in gastric carcinoma
por: Kim, Min A, et al.
Publicado: (2011)

The Relationship between Self-Perceived Burden and Posttraumatic Growth among Colorectal Cancer Patients: The Mediating Effects of Resilience
por: Zhang, Chengshuai, et al.
Publicado: (2019)

Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas
por: Zoi, Ilianna, et al.
Publicado: (2019)

ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells
por: Valabrega, G, et al.
Publicado: (2003)

DMBA promotes ErbB2-mediated carcinogenesis via ErbB2 and estrogen receptor pathway activation and genomic instability
por: Ma, Zhikun, et al.
Publicado: (2018)

CD74-NRG1 Fusions Are Oncogenic In Vivo and Induce Therapeutically Tractable ERBB2:ERBB3 Heterodimerization
por: Werr, Lisa, et al.
Publicado: (2022)

Targeted therapeutics in SLE: emerging strategies to modulate the interferon pathway
por: Oon, Shereen, et al.
Publicado: (2016)

Implications of hydrogen sulfide in colorectal cancer: Mechanistic insights and diagnostic and therapeutic strategies
por: Lin, Hanchao, et al.
Publicado: (2023)

BRAF mutant colorectal cancer: ErbB2 expression levels as predictive factor for the response to combined BRAF/ErbB inhibitors
por: Miele, Evelina, et al.
Publicado: (2020)

Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer
por: Mitsui, Keigo, et al.
Publicado: (2014)

Pathway pathology: the wnt and erbB mammary tumors
por: Rosner, A, et al.
Publicado: (2001)

Modulation of ErbB2 Blockade in ErbB2-Positive Cancers: The Role of ErbB2 Mutations and PHLDA1
por: Li, Guangyuan, et al.
Publicado: (2014)

Destabilized 3’UTR elements therapeutically degrade ERBB2 mRNA in drug-resistant ERBB2+ cancer models
por: Awah, Chidiebere U., et al.
Publicado: (2023)

Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer
por: Zhang, Jinrui, et al.
Publicado: (2019)

The chromodomain helicase CHD4 regulates ERBB2 signaling pathway and autophagy in ERBB2(+) breast cancer cells
por: D'Alesio, Carolina, et al.
Publicado: (2019)

ERBB3 binding protein 1 promotes the progression of malignant melanoma through activation of the Wnt/ β-catenin signaling pathway
por: Bao, Yanqiu, et al.
Publicado: (2022)

Inhibition of DDR1‐BCR signalling by nilotinib as a new therapeutic strategy for metastatic colorectal cancer
por: Jeitany, Maya, et al.
Publicado: (2018)

Management of BRAF Gene Alterations in Metastatic Colorectal Cancer: From Current Therapeutic Strategies to Future Perspectives
por: Takeda, Hiroyuki, et al.
Publicado: (2021)

RNA binding protein CUGBP1 mediates the liver metastasis of colorectal cancer by regulating the ErbB signal pathway
por: Qi, Zhi-Peng, et al.
Publicado: (2021)

PTPRO represses ERBB2-driven breast oncogenesis by dephosphorylation and endosomal internalization of ERBB2
por: Dong, H, et al.
Publicado: (2017)

Quantitative Phosphoproteomics Analysis of ERBB3/ERBB4 Signaling
por: Wandinger, Sebastian K., et al.
Publicado: (2016)

Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer
por: Zhao, Lei, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_1i0msi1c64rcbl1hgdpi3ehndg